Skip to main content

Pharma News

academics

 

Clinical research courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Peanuts and herbs and spices may positively impact gut microbiome

    Adding a daily ounce of peanuts or about a teaspoon of herbs and spices to your diet may affect the composition of gut bacteria, an indicator of overall health, according to new research from Penn State. In two separate studies, nutritional scientists studied the effects of small changes to the average American diet and found improvements to the gut microbiome.

  • Scientists reveal encouraging findings in first-in-human clinical trial evaluating HIV vaccine approach

    While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy being pursued by researchers at Scripps Research, IAVI, Fred Hutchinson Cancer Center (Fred Hutch) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) shows new promise, according to data from a first-in-human clinical trial.

  • Lupin Launches Rufinamide Tablets USP in the United States

    Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

  • Indian Pharmacopoeia to become digital

    At the pinnacle of the online era, the Indian Pharmacopoeia Commission (IPC) is set to digitize Indian Pharmacopoeia (IP) to increase its coverage.

    IPC has invited tender on Gem Portal (Government E Marketplace) from eligible and qualified IT firms related to online portal Development, application development, data digitalization or online content management etc for the project.

  • FDA lays aside Lillys Bebtelovimab in the U.S.

    FDA lays aside Lilly's bebtelovimab in the U.S. for emergency use treatment of mild-to-moderate COVID-19 in adults and pediatric patients. Over the last several months, prevalence of COVID variant sublineages vary by state, region and even country, and can change rapidly.

    Lilly said that it agrees with the FDA that it is not medically appropriate, at this time, to treat high-risk patients with mild-to-moderate COVID-19 with bebtelovimab in the US.

  • Alembic Pharma receives USFDA Approval for Diclofenac Sodium Topical Solution

    Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.

  • Mrs. Archna Mudgal has taken voluntary retirement from PCI

    Mrs. Archna Mudgal who was serving as registrar cum secretary has taken voluntary retirement from PCI, notified by Pharmacy council of India. And Mr Anil Mittal, Deputy Secretary has taken charge as Registrar-cum-Secretary.

    A notification published on Pharmacy Council of India (PCI) portal said, "Due to Voluntary Retirement taken by Smt. Archna Mudgal, Registrar-cum-Secretary, PCI, Shri Anil Mittal, Deputy Secretary will hold the charge of Registrar-cum-Secretary."

  • Gland Pharma acquires Europe based Cenexi Group

    The Singapore based subsidiary of Gland Pharma has acquired Europe based Cenexi Group which is engaged primarily in the business of Contract Development & Manufacturing Organisation (CDMO) of pharmaceutical products with expertise in sterile liquid and lyophilized fill- finished drugs, including capabilities on oncology and complex products.

    The Gland Pharma entered into a put option agreement to acquire 100 percent of Cenexi Group for an Equity Value not exceeding Euro 120 Mn (Enterprise Value of Euro 230 Mn).

  • Boston Scientific Announces agreement to acquire Apollo Endosurgery, Inc.

    Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Apollo Endosurgery, Inc for a cash price of 10 USD per share, reflecting an enterprise value of approximately 615 million USD.

  • AstraZeneca to sale its US based plant

    AstraZeneca announces the sale of its West Chester site in Ohio, US, to National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines.

Subscribe to Pharma News